You are here:

Archived: pegylated liposomal doxorubicin (Caelyx)

Advice

Following a full submission

pegylated liposomal doxorubicin (Caelyx®) is not recommended for use within NHS Scotland in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.

Results from an interim analysis showed that pegylated liposomal doxorubicin plus bortezomib significantly increased the time to progression compared to bortezomib monotherapy. At the time of the interim analysis only 31% of patients in the combination arm had reached the primary endpoint.

The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Drug Details

Drug Name: pegylated liposomal doxorubicin (Caelyx)
SMC Drug ID: 503/08
Manufacturer: Schering-Plough Ltd
Indication: Progressive multiple myeloma in patients who have received at least one prior therapy
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 13 October 2008

Current Advice

Resubmission 13 July 2009

Back